Skip to content
DraconiticResearch
Search Sources API
226,742 studies31 sourcesUpdated 6 min ago
Peer-reviewedCC BY-NC 4.0Infectious Diseases and Therapy

Complicated Urinary Tract Infections Caused by Fluoroquinolone-Non-Susceptible/Trimethoprim-Sulfamethoxazole-Resistant Extended-Spectrum β-Lactamase-Producing Enterobacterales: Patient Characteristics, Resistance Phenotypes, Treatment Patterns, and Clinical Outcomes

6 affiliations
  1. 1University of Pittsburgh, Pittsburgh, PA USA
  2. 2David Geffen School of Medicine at UCLA, Los Angeles, CA USA
  3. 3GSK, London, UK
  4. 4Analysis Group Inc., Boston, MA USA
  5. 5Analysis Group Inc., Los Angeles, CA USA
  6. 6GSK, 1250 S, Collegeville Road, Collegeville, PA 19426 USA

Abstract

Introduction: Patients with complicated urinary tract infections (cUTIs) caused by extended-spectrum β-lactamase (ESBL)-producing Enterobacterales (ESBL-E) not susceptible (NS) to fluoroquinolones (FQ-NS) or resistant (R) to trimethoprim-sulfamethoxazole (TMP/SMX-R) have few effective oral treatment options.

Methods: Data from the Optum de-identified Electronic Health Record data set (Optum EHR) (January 2018–September 2023) were used. The primary objective was to describe cumulative incidence of treatment failure (TF) by care setting (hospital versus non-hospital) within 30 days of the initiation of the latest intravenous antibiotic treatment prescribed ± 7 days from the microbiology results (index).

Results: Among 7388 eligible patients, mean (standard deviation) age was 65.6 (17.7) years, and 66.3% were female. Most patients (5211, 70.5%) had a cUTI with a complicating factor; 3415 (46.2%) were diagnosed in hospital. Among the 7902 ESBL-E isolates from eligible patients with cUTIs, Escherichia coli was the predominant pathogen (75.1%), followed by Klebsiella pneumoniae (13.4%). Overall, 6384 (81.7%) isolates were FQ-NS, 5323 (68.0%) TMP/SMX-R, and 170 (2.2%) carbapenem-NS. Kaplan-Meier estimates revealed that the cumulative incidence of TF by day 30 post-index was 27.5% among hospitalized patients and 25.2% among non-hospitalized, with variation by resistance profile, driven primarily by receipt of another antibiotic (both settings). Most patients (5013, 67.9%) were prescribed an intravenous antibiotic at index, often carbapenems (2157, 43.0%), but treatment sequences were heterogeneous. Recurrence occurred in 2116 patients (28.6%), hospitalization (among those not hospitalized at index) in 975 (24.5%), and readmission in 663 (19.4%).

Conclusions: These data indicate a substantial burden of cUTIs caused by ESBL-E that were FQ-NS or TMP/SMX-R, characterized by high rates of treatment failures and hospitalization for IV antibiotic treatment.

Supplementary Information: The online version contains supplementary material available at https://doi.org/10.1007/s40121-026-01460-y.

Related

  1. Disseminated Trimethoprim/Sulfamethoxazole–Resistant Nocardiosis in Renal Transplant Recipient, India
    Sandeep Rao Kordcal, Md Tariq Maula, Vivek Malleshappa Suguna +8
    Emerging Infectious DiseasesPeer-reviewedCC BY 4.0Full textInfectious diseaseDOAJPMC
  2. Drug-Induced Immune Thrombocytopenia Caused by Sulfamethoxazole-Trimethoprim: A Case Report
    Alec Powell, Louisa Weindruch, Jonathan Thornton
    Clinical practice and cases in emergency medicinePeer-reviewedCC BYFull textGeneral medicineEurope PMCPMC
  3. Single-strength trimethoprim/sulfamethoxazole (TMP/SMX)-induced hypoglycaemia in a post kidney-pancreas transplant patient
    Naseeruddin Khan, Numair Khan, Irfan Agha +1
    BMJ Case ReportsPeer-reviewedCC BY-NC 4.0Full textSurgery & anaesthesiaPMC
  4. Evolutionary Convergence on a Dihydrofolate Reductase Mutation Drives Trimethoprim–Sulfamethoxazole Resistance in Burkholderia thailandensis
    Sophie Guillier, Christine Lazennec-Schurdevin, Lou Mondange +9
    ACS Infectious DiseasesPeer-reviewedCC BY-NC-ND 4.0Full textEpidemiology & public healthHAL
  5. Clinical Outcomes of Trimethoprim-Sulfamethoxazole with or Without Adjunctive Caspofungin in Patients with Moderate-to-Severe HIV-Associated Pneumocystis jirovecii Pneumonia: A Retrospective Cohort Study
    Yu Wang, Caopei Zheng, Yuqing Sun +1
    Infection and Drug ResistancePeer-reviewedCC BY-NC 4.0Full textEpidemiology & public healthPMC
BibTeX
@article{shields2026complicated,
  title = {{Complicated Urinary Tract Infections Caused by Fluoroquinolone-Non-Susceptible/Trimethoprim-Sulfamethoxazole-Resistant Extended-Spectrum β-Lactamase-Producing Enterobacterales: Patient Characteristics, Resistance Phenotypes, Treatment Patterns, and Clinical Outcomes}},
  author = {Ryan K. Shields and A. Lenore Ackerman and Myriam Drysdale and Rose Chang and Louise Yu and Maral DerSarkissian and Iain A. Gillespie and Megan Pinaire and Zhuo Chen and Mei Sheng Duh and Alanna Farrell-Foster and Fanny S. Mitrani-Gold},
  journal = {Infectious Diseases and Therapy},
  year = {2026},
  month = oct,
  doi = {10.1007/s40121-026-01460-y},
  url = {https://doi.org/10.1007/s40121-026-01460-y},
  note = {CC BY-NC 4.0},
}
RIS
TY  - JOUR
TI  - Complicated Urinary Tract Infections Caused by Fluoroquinolone-Non-Susceptible/Trimethoprim-Sulfamethoxazole-Resistant Extended-Spectrum β-Lactamase-Producing Enterobacterales: Patient Characteristics, Resistance Phenotypes, Treatment Patterns, and Clinical Outcomes
AU  - Ryan K. Shields
AU  - A. Lenore Ackerman
AU  - Myriam Drysdale
AU  - Rose Chang
AU  - Louise Yu
AU  - Maral DerSarkissian
AU  - Iain A. Gillespie
AU  - Megan Pinaire
AU  - Zhuo Chen
AU  - Mei Sheng Duh
AU  - Alanna Farrell-Foster
AU  - Fanny S. Mitrani-Gold
PY  - 2026
DA  - 2026/10/12
JO  - Infectious Diseases and Therapy
DO  - 10.1007/s40121-026-01460-y
UR  - https://doi.org/10.1007/s40121-026-01460-y
AB  - Introduction: Patients with complicated urinary tract infections (cUTIs) caused by extended-spectrum β-lactamase (ESBL)-producing Enterobacterales (ESBL-E) not susceptible (NS) to fluoroquinolones (FQ-NS) or resistant (R) to trimethoprim-sulfamethoxazole (TMP/SMX-R) have few effective oral treatment options.  Methods: Data from the Optum de-identified Electronic Health Record data set (Optum EHR) (January 2018–September 2023) were used. The primary objective was to describe cumulative incidence of treatment failure (TF) by care setting (hospital versus non-hospital) within 30 days of the initiation of the latest intravenous antibiotic treatment prescribed ± 7 days from the microbiology results (index).  Results: Among 7388 eligible patients, mean (standard deviation) age was 65.6 (17.7) years, and 66.3% were female. Most patients (5211, 70.5%) had a cUTI with a complicating factor; 3415 (46.2%) were diagnosed in hospital. Among the 7902 ESBL-E isolates from eligible patients with cUTIs, Escherichia coli was the predominant pathogen (75.1%), followed by Klebsiella pneumoniae (13.4%). Overall, 6384 (81.7%) isolates were FQ-NS, 5323 (68.0%) TMP/SMX-R, and 170 (2.2%) carbapenem-NS. Kaplan-Meier estimates revealed that the cumulative incidence of TF by day 30 post-index was 27.5% among hospitalized patients and 25.2% among non-hospitalized, with variation by resistance profile, driven primarily by receipt of another antibiotic (both settings). Most patients (5013, 67.9%) were prescribed an intravenous antibiotic at index, often carbapenems (2157, 43.0%), but treatment sequences were heterogeneous. Recurrence occurred in 2116 patients (28.6%), hospitalization (among those not hospitalized at index) in 975 (24.5%), and readmission in 663 (19.4%).  Conclusions: These data indicate a substantial burden of cUTIs caused by ESBL-E that were FQ-NS or TMP/SMX-R, characterized by high rates of treatment failures and hospitalization for IV antibiotic treatment.  Supplementary Information: The online version contains supplementary material available at https://doi.org/10.1007/s40121-026-01460-y.
SN  - 2193-8229
SN  - 2193-6382
ER  -